Global Companion Diagnostics Market 2021

January 2022 | 21 pages | ID: G26A2286F9D5EN
StrategyHelix Inc

Abstracts

The global companion diagnostics market is poised to grow by US$ 6,438 million during 2021-2027, progressing at a CAGR of 13.7% during the forecast period, according to data and analytics company StrategyHelix. Rising geriatric population, rising prevalence of cancer, companies promoting personalized medicine and targeted therapy as new treatment options, co-development of drugs and diagnostics are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for companion diagnostics. The global companion diagnostics market is segmented on the basis of product, technology, indication, and region. By product, the global companion diagnostics market has been segmented into consumables, instruments, services. The consumables segment was the largest contributor to the global companion diagnostics market in 2020. Based upon technology, the global companion diagnostics market is categorized into immunohistochemistry (IHC), polymerase chain reaction (PCR), in situ hybridization (ISH), next-generation sequencing (NGS), others. According to the research, the polymerase chain reaction (PCR) segment had the largest share in the global companion diagnostics market. On the basis of indication, the global companion diagnostics market has been segmented into lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, others. The lung cancer segment held the largest revenue share in 2020. Geographically, the global companion diagnostics market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global companion diagnostics market is highly competitive. The leading players in the companion diagnostics market include Abbott Laboratories, Agilent Technologies Inc. (Dako A/S), ARUP Laboratories Inc., bioMerieux SA, Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina Inc., MolecularMD Corp. (ICON plc), Myriad Genetic Laboratories Inc., QIAGEN N.V., Thermo Fisher Scientific Inc.

Report Scope
Product: consumables, instruments, services
Technology: immunohistochemistry (IHC), polymerase chain reaction (PCR), in situ hybridization (ISH), next-generation sequencing (NGS), others
Indication: lung cancer, breast cancer, colorectal cancer, leukemia, melanoma, others
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global companion diagnostics market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. COMPANION DIAGNOSTICS MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Consumables
Instruments
Services

PART 4. MARKET BREAKDOWN BY TECHNOLOGY

Immunohistochemistry (IHC)
Polymerase chain reaction (PCR)
In situ hybridization (ISH)
Next-generation sequencing (NGS)
Others

PART 5. MARKET BREAKDOWN BY INDICATION

Lung cancer
Breast cancer
Colorectal cancer
Leukemia
Melanoma
Others

PART 6. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 7. KEY COMPANIES

Abbott Laboratories
Agilent Technologies Inc. (Dako A/S)
ARUP Laboratories Inc.
bioMerieux SA
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Illumina Inc.
MolecularMD Corp. (ICON plc)
Myriad Genetic Laboratories Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
About StrategyHelix
Disclaimer